Alzheimer's disease is a degenerative condition affecting the brain and is the most common form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people. The progression of the disease varies between individuals and the early stages may be characterised by only minimal changes in memory and thinking. These changes could remain undetected as the symptoms may be mistakenly regarded as normal age-related forgetfulness. However, dementia is not part of the normal ageing process.
The underlying biological disease process of Alzheimer's is now known to start at least 20 years prior to patients showing any symptoms. A protein called amyloid starts to deposit in the brain and forms clumps referred to as 'plaques'. Another protein called tau collects inside brain cells and forms structures called 'tangles'. These biological changes can disrupt the normal functioning of brain cells and ultimately destroy them, leading to a reduction in brain volume and ability.
The aim of the BEAD-PC study is to assess whether a specific blood test in primary care can help diagnose Alzheimer's disease at an early stage.
Age 55 years and above
Presence of self-reported symptoms indicative of cognitive decline or concerns family members/partners indicative of cognitive decline
Capacity to consent
Be fluent in and able to read and write in English and have adequate hearing and visual acuity to complete the required psychometric tests.
Insufficient vision and hearing
Prior diagnosis of ADRD. Prior diagnosis of Alzheimer's disease or related dementia (with or without evidence of pathology), through clinical diagnosis and/or as documented in their medical record
Pre-existing diagnosis of dementia
Incidental findings of brain pathologies on brain MRI, such as cancerous space occupying lesions and clinically significant vascular malformations and recent (within 12 months) macro-infarcts, that are, also exclusionary
Eligible patients from 124 GP surgeries England.
Ecologic or community
Prospective
Not listed
Presence of Alzheimer-specific blood biomarkers
Amyloid and Tau protein biomarkers identified in blood sample
Presence of Alzheimer-specific Cerebrospinal Fluid (CSF) biomarkers
Amyloid and Tau protein biomarkers found in CSF
Montreal Cognitive Assessment (MoCA) score
Pen-and-paper cognitive test commonly used to identify Mild Cognitive Impairment (MCI) in older adults.
CANTAB score
Online, self-completed battery of cognitive tests validated for detecting signs of AD-related cognitive decline.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
